Institute for Quality and Efficiency in Health Care

Palliation is rarely a topic in studies on advanced cancer

End-of-life aspects, the corresponding terminology, and the relevance of palliation in advanced cancer are often not considered in publications on randomized controlled trials (RCTs). This is the result of an analysis by ...

16 hours ago
popularity not rated yet | comments 0

Dabrafenib: Also no added benefit over vemurafenib

Dabrafenib (trade name: Tafinlar) has been approved since August 2013 for the treatment of advanced melanoma. In January 2014, in an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal ...

Apr 09, 2014
popularity not rated yet | comments 0